One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

This effort aligns with the objectives of Saudi Vision 2030, which aims to address the clinical and economic challenges posed ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Novo Nordisk India Pvt Ltd (NNIPL) and the Indian Institute of Management Ahmedabad (IIMA) have signed a Memorandum of ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...